Key takeaways
Remicade (infliximab) and Entyvio (vedolizumab) are both medications used to autoimmune conditions, but they work differently and have different administration methods. Both medications treat Crohn's disease (CD) and ulcerative colitis (UC). Remicade is also used to treat other autoimmune conditions like rheumatoid arthritis and psoriasis, while Entyvio is not. Remicade can be used in children 6 years and older for certain conditions, while Entyvio is only approved for adults. Remicade blocks a protein called tumor necrosis factor (TNF), which helps reduce inflammation. It is given through an IV infusion by a healthcare provider. In contrast, Entyvio blocks certain proteins found on immune cells to help lower inflammation. Entyvio can be given either as an IV infusion or as an injection under the skin. Both medications can cause serious side effects, including infusion reaction, infections and liver problems, but Remicade has additional risks like heart issues.
